GSK commits $345M to Vir as alliance expands to flu, other respiratory viruses February 17, 2021 Auto Bot BioPharma, biopharma nl, Coronavirus (COVID-19), GlaxoSmithKline, influenza, Pharma, SAN FRANCISCO 0 The amended pact follows a collaboration begun last year when GlaxoSmithKline paid Vir Biotechnology $250 million to team up on potential treatments for Covid-19. The expansion includes an influenza treatment based on Vir’s antibody technology.